Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Irinotecan Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 21,451Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
    Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri

    19 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/19/2932080/0/en/Processa-Pharmaceuticals-Announces-Positive-Preclinical-Data-for-NGC-Iri.html

    GLOBENEWSWIRE
    19 Aug 2024
    Share Share
    Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
    Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

    14 Feb 2024

    // PRESS RELEASE

    https://investors.merrimack.com/news-releases/news-release-details/merrimack-reports-ipsen-announcement-approval-us-fda-onivyder

    PRESS RELEASE
    14 Feb 2024
    Share Share
    Ipsen announces U.S. FDA submission acceptance of its sN DA for Onivyde
    Ipsen announces U.S. FDA submission acceptance of its sN DA for Onivyde

    14 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/14/2688483/0/en/Correction-Ipsen-announces-U-S-FDA-submission-acceptance-of-its-supplemental-New-Drug-Application-for-Onivyde-regimen-in-first-line-metastatic-pancreatic-ductal-adenocarcinoma.html

    GLOBENEWSWIRE
    14 Jun 2023
    Share Share
    Edison Oncology Announces Presentation of Two Scientific Posters at AACR Meeting
    Edison Oncology Announces Presentation of Two Scientific Posters at AACR Meeting

    20 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/edison-oncology-announces-presentation-of-two-scientific-posters-at-aacr-annual-meeting-301803139.html

    PR NEWSWIRE
    20 Apr 2023
    Share Share
    Ipsen's Onivyde turns in positive results in pancreatic cancer
    Ipsen's Onivyde turns in positive results in pancreatic cancer

    21 Jan 2023

    // Zoey Becker FIERCE PHARMA

    https://www.fiercepharma.com/pharma/ipsens-onivyde-proves-its-worth-previously-untreated-specific-pancreatic-cancer

    Zoey Becker FIERCE PHARMA
    21 Jan 2023
    Share Share
    RRx-001 + Irinotecan Significantly Improved PFS Versus Regorafenib in PII Trial
    RRx-001 + Irinotecan Significantly Improved PFS Versus Regorafenib in PII Trial

    14 Dec 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/rrx-001--irinotecan-significantly-improved-progression-free-survival-pfs-versus-regorafenib-in-the-randomized-phase-2-rocket-trial-in-advanced-colorectal-cancer-301702337.html

    PRNEWSWIRE
    14 Dec 2022
    Share Share